Search clinical trials for: Nitazoxanide and atazanavir/ritonavir

Total 1040 results

Obafemi Awolowo University
University of Liverpool; Olabisi Onabanjo University Teaching Hospital; African... and other collaborators

Terminated

The Nitazoxanide Plus Atazanavir for COVID-19 Study (NACOVID)

Covid-19

Nigeria
Obafemi Awolowo University
University of Liverpool

Completed

Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers

Drug Interaction

Nigeria
Asan Medical Center
Bristol-Myers Squibb

Unknown

Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers

Atazanavir

Korea, Republic of
Giovanni Di Perri
University of Turin, Italy; University of Milan

Terminated

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir (RALBAT)

HIV Infection | Osteopenia

Italy
Bristol-Myers Squibb

Completed

Drug Interaction Study With Proton Pump Inhibitor

HIV Infections

United States
Bristol-Myers Squibb

Completed

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

HIV Infections

United States
University of Liverpool
University of Cape Town; Desmond Tutu HIV Foundation; Infectious Diseases Institute... and other collaborators

Completed

Pharmacokinetics of Atazanavir in Special Populations (VirTUAL WP5)

HIV/AIDS | Tuberculosis

Uganda, South Africa
Bristol-Myers Squibb

Completed

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) (PRINCE1)

HIV Infections

Thailand, Chile, Peru, Brazil, Mexico, South Africa
University of California, San Francisco

Completed

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Healthy

United States
Fundacion SEIMC-GESIDA
Bristol-Myers Squibb

Completed

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy (SALT)

HIV Infection

Spain
Bristol-Myers Squibb

Completed

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

HIV Infections

United States, United Kingdom
University of British Columbia

Completed

Switch to Unboosted Atazanavir With Tenofovir Study (SUAT)

HIV Infection

Canada
Bristol-Myers Squibb

Completed

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

HIV

Argentina, France, Taiwan, Thailand, United States, Chile, Spain, Dominican Republic, Guatemala, Peru, Puerto Rico, Singapore, Russian Federation, Italy, Mexico, Colombia, South Africa, Brazil, Hungary, Malaysia, Portugal, Canada, I... and more
Bristol-Myers Squibb

Completed

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) (INDUMA)

HIV Infections

Spain, Italy, United Kingdom, France, Russian Federation, Ireland, Germany, Latvia, Estonia, Portugal
Catholic University of the Sacred Heart

Completed

Atazanavir/r + Lamivudine Dual Therapy (ATLAS)

Human Immunodeficiency Virus

Italy
International Antiviral Therapy Evaluation Center
Gilead Sciences; Hoffmann-La Roche

Completed

BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes

HIV Infections

Netherlands
Bristol-Myers Squibb

Completed

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

HIV Infections

United States, Puerto Rico
St. James's Hospital, Ireland

Unknown

Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users

HIV Infections | Hepatitis C

Ireland
International Medical Center of Japan
Ministry of Health, Labour and Welfare, Japan

Completed

Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment

HIV Infections

Japan
Bristol-Myers Squibb

Completed

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

HIV Infections

United States
Bristol-Myers Squibb

Completed

ATV/Ritonavir Nevirapine Interaction (USPAC)

HIV Infections

United Kingdom, United States
Bristol-Myers Squibb

Completed

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

HIV Infections

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Metabolic Effects of Switching Kaletra to Boosted Reyataz

HIV Infections

United States
The University of Texas Health Science Center,...

Completed

"The Once A Day Protease Inhibitor Regimens"

HIV Infections

United States
St Stephens Aids Trust

Completed

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

HIV Infections | HIV

United Kingdom
Bristol-Myers Squibb

Completed

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

HIV Infections

United States
Kenneth H. Mayer, MD
Bristol-Myers Squibb; Gilead Sciences; Abbott

Terminated

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (BMS PEP)

HIV

United States
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Endothelial Dysfunction

United States
Catholic University of the Sacred Heart

Completed

Atazanavir and Lamivudine for Treatment Simplification (AtLaS)

HIV Infections

Italy
Bristol-Myers Squibb

Completed

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression (OREY)

Human Immunodeficiency Virus (HIV) Infections

Spain
Clinical Alliance for Research & Education - Infectious...
GlaxoSmithKline

Unknown

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

HIV Infections | Lipodystrophy

United States
IRCCS San Raffaele
Bristol-Myers Squibb

Completed

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

HIV-1 Infection

Italy
Bristol-Myers Squibb

Completed

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

HIV Infections

United States, Canada, Argentina, Belgium, Chile, Mexico, Spain, Italy, Australia, Brazil, France, Puerto Rico, United Kingdom, Netherlands, Peru
Centre de Recherches et d'Etude sur la Pathologie...
INSERM UMR S 1136

Completed

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients (ATALOW)

HIV-1 Infection

France
Ottawa Hospital Research Institute
Bristol-Myers Squibb

Completed

Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study

HIV Infection

Canada
McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC; CIHR Canadian HIV Trials Network

Completed

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Hepatitis C | HIV | Liver Fibrosis

Canada
Telethon Kids Institute

Withdrawn

Finding Better Treatment of Bronchiolitis: A Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments

Bronchiolitis

Australia
University of Liverpool
Janssen Pharmaceutica; Yaounde Central Hospital; Chantal Biya International Reference...

Completed

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS (MANET)

HIV/AIDS

Cameroon
ViiV Healthcare
GlaxoSmithKline

Completed

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
Azidus Brasil
Farmoquimica S.A.; Hospital Vera Cruz; Hospital Casa de Saúde - Vera Cruz - Campinas... and other collaborators

Completed

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

COVID-19

Brazil
Juan A. Arnaiz

Completed

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

HIV-1

Spain
Hospitales Universitarios Virgen del Rocío
Bristol-Myers Squibb

Completed

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

HIV Infection | Hepatitis C, Chronic

Spain
University Hospital, Bonn
Dr. Axel Baumgarten, Berlin; Dr. Christoph Stephan, Frankfurt/M; Dr. Stefan Esser... and other collaborators

Withdrawn

Safety Study of Raltegravir in HIV/HCV Co-infected Patients

Hepatitis C | HIV

Germany
Bristol-Myers Squibb

Completed

Drug Interaction Study

Antivirals/HIV

United States
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Healthy

United States
Bristol-Myers Squibb

Completed

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

HIV Infections

United States, Canada
Romark Laboratories L.C.

Completed

Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children

Rotavirus Infection | Norovirus Infection | Adenoviridae Infection
Bristol-Myers Squibb

Completed

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

HIV Infections | Protease Inhibitor

United States
Azidus Brasil
Farmoquimica S.A.

Recruiting

Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

covid19

Brazil

Search clinical trials for: Nitazoxanide and atazanavir/ritonavir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations